Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of
EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study …

Importance The combination of erlotinib and bevacizumab as initial treatment of epidermal
growth factor receptor (EGFR [OMIM131550])–mutant lung cancers improves progression …

Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …

Methylthioadenosine phosphorylase, an essential enzyme for the adenine salvage pathway,
is often deficient (MTAPdef) in tumors with 9p21 loss and hypothetically renders tumors …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …

Before the introduction of tyrosine kinase inhibitors (TKIs) for a particular subgroup of
patients, despite platinum-based combination chemotherapy, the majority of patients …

The tyrosine kinase activity of epidermal growth factor receptors (EGFRs) plays critical roles
in cell proliferation, regeneration, tumorigenesis, and anticancer resistance. Non-small-cell …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …